VCYT•Veracyte’s third-quarter 2026 net income rose 65% year over year to $31.5 million, while revenue increased 15% to $151.8 million. The company authorized up to $100 million in stock repurchases, acquired Convergent Genomics and narrowed its full-year revenue guidance.
Veracyte reported third-quarter net income of $31.5 million, up 65% year over year, and revenue of $151.8 million, up 15%. Operating income fell 28% to $16.57 million. The board authorized up to $100 million in common stock repurchases, and the company acquired bladder cancer testing developer Convergent Genomics.
Veracyte narrowed its full-year 2026 revenue guidance to $590 million–$593 million, from $590 million–$596 million.
